Joshua Richter, MD

Expert hematologist/oncologists review the case of a 69-year-old man with multiple myeloma who had a biochemical relapse and share their approaches to treatment.

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses the findings from a study on the incidence and survival impact of self-reported symptom and psychological distress for patients with multiple myeloma.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center discusses symptom management in patients with multiple myeloma.

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the use of novel oral anticoagulants for use in patients with hematologic malignancies.

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the administration of carfilzomib.